ACOG

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. "On behalf of the entire Board of Directors, we are pleased that Dr. Wills will serve as Chairman at this important time for Alpha Cognition," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "He brings a wealth of experience, strategic insight, and a deep understanding of our busi

Alpha Cognition, Inc. (ACOG: NASDAQ) ("Alpha Cognition" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a multicenter, post-approval Phase 4 study designed to further evaluate the tolerability profile of ZUNVEYL in clinical practice, in patients with Alzheimer's disease. The study will collect safety and tolerability data and will also explore changes in Alzheimer's dise

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

In a retrospective observational study based on provider assessments and chart review: Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL Providers reported favo

4 - Alpha Cognition Inc. (0001655923) (Issuer)

Maxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00

4 - Alpha Cognition Inc. (0001655923) (Issuer)

SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

10-Q - Alpha Cognition Inc. (0001655923) (Filer)

SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

8-K/A - Alpha Cognition Inc. (0001655923) (Filer)

DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)

DEFA14A - Alpha Cognition Inc. (0001655923) (Filer)

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

Alpha Cognition, Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum's 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28,

8-K - Alpha Cognition Inc. (0001655923) (Filer)

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

4 - Alpha Cognition Inc. (0001655923) (Issuer)

3 - Alpha Cognition Inc. (0001655923) (Issuer)

Craig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00